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OBSTETRICS
Plasma biomarker discovery in preeclampsia
using a novel differential isolation technology
for circulating extracellular vesicles
Kok Hian Tan, MBBS; Soon Sim Tan, BSc; Siu Kwan Sze, PhD;
Wai Kheong Ryan Lee, MBBS; Mor Jack Ng, BSc; Sai Kiang Lim, PhD
OBJECTIVE: To circumvent the complex protein milieu of plasma and pro-calcitonin, S100b, tumor growth factor b, vascular endothelial
discover robust predictive biomarkers for preeclampsia (PE), we inves-
tigate if phospholipid-binding ligands can reduce the milieu complexity
by extracting plasma extracellular vesicles for biomarker discovery.
STUDY DESIGN: Cholera toxin B chain (CTB) and annexin V (AV) which
respectively binds GM1 ganglioside and phosphatidylserine were used
to isolate extracellular vesicles from plasma of PE patients and healthy
pregnant women. The proteins in the vesicles were identified using
enzyme-linked immunosorbent assay, antibody array, and mass
spectrometry.
RESULTS: CTB and AV were found to bind 2 distinct groups of
extracellular vesicles. Antibody array and enzyme-linked immuno-
sorbent assay revealed that PE patients had elevated levels of CD105,
interleukin-6, placental growth factor, tissue inhibitor of metal-
lopeptidase 1, and atrial natriuretic peptide in cholera toxin B- but not
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Open access under CC BY-NC-ND license.growth factor receptor 1, brain natriuretic peptide, and placental growth
factor in both cholera toxin B- and AV-vesicles. CD9 level was elevated
in cholera toxin B-vesicles but reduced in AV vesicles of PE patients.
Proteome analysis revealed that in cholera toxin B-vesicles, 87 and
222 proteins were present only in PE patients and healthy pregnant
women respectively while in AV-vesicles, 104 and 157 proteins were
present only in PE and healthy pregnant women, respectively.
CONCLUSION: This study demonstrated for the first time that CTB and
AV bind unique extracellular vesicles, and their protein cargo reflects
the disease state of the patient. The successful use of these 2 ligands
to isolate circulating plasma extracellular vesicles for biomarker dis-
covery in PE represents a novel technology for biomarker discovery
that can be applied to other specialties.
Key words: annexin V, biomarker discovery, cholera toxin B chain,
extracellular vesicles, preeclampsiaCite this article as: Tan KH, Tan SS, Sze SK, et al. Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular
vesicles. Am J Obstet Gynecol 2014;211:380.e1-13.reeclampsia (PE) remains one ofP themost common causes of adverse
pregnancy outcome in developed and
developing countries. The incidence of
PE is substantial, about 3% to 8%.1,2 PE
places the obstetric patient and her in-
fant at substantial risk of preterm birth
and perinatal mortality, and severematernal hypertension and multi-
systemic organ dysfunction and damage,
including eclampsia and abruption
placentae.3,4 Predictive tests for pre-
eclampsia early in the course of preg-
nancy would provide sufﬁcient time to
intervene and mitigate the risks of PE.
There has been an intense interest in’s Hospital
ore (Dr K.H. Tan);
logical Sciences,
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C) - A*STAR, KK
Council (NMRC).
linical Program
spital, 100 Bukitbiomarkers for the identiﬁcation of pa-
tients at risk for preeclampsia. Although
clinical risk factors for preeclampsia are
well known, these factors either singly or
in combination have limited predictive
values and this has led to intense search
for predictive biomarkers for PE, par-
ticularly in plasma.5 However, plasma-
derived predictive biomarkers like the
generic disease biomarkers are generally
low abundance proteins and their dis-
covery is confounded by the dominance
of several high abundance proteins such
as albumin and immunoglobulins. De-
spite much effort to eliminate or reduce
these abundant proteins, circumventing
these high abundance plasma proteins
remains a challenge. However, the recent
extraction of membrane vesicles from
bodily ﬂuids such as plasma or urine6
for biomarker discovery inadvertently
resolved this challenge as removal of
the high abundance plasma proteins is
FIGURE 1
Protein profile of CTB- or AV-vesicles in human plasma
5 mL plasma from a healthy donor was incubated with biotinylated cholera toxin B chain (CTB) or
with biotinylated annexin V (AV). Bound vesicles were extracted with Dynabeads MyOne Streptavidin
T1 (Life Technologies, Grand Island, NY) magnetic beads. The beads were boiled in standard sodium
dodecyl sulfate polyacrylamide gel electrophoresis loading buffer and loaded on 4-12% gradient gel
and the gel was then silver stained. Lane 1 was molecular weight (MW) marker; lane 2 and 3 were
controls without plasma; lane 4 and 5 were CTB- or AV-bound vesicles from plasma; lane 6 and 7
were plasma. Arrows indicated protein bands unique to either CTB- or AV-bound vesicles.
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vesicles.
The cell sources of these circulating
vesicles are likely to be diverse as many
cell types are known to secrete mem-
brane vesicles. Because these vesicles are
essentially fragments of the secreting
cells, they and their cargo are micro-
cosms of their cell sources and would
reﬂect the physiologic or diseased state
of the cells, making them potential
sources of biomarkers for disease diag-
nosis or prognosis.7 Indeed, pregnancy-
associated exosomes were reported as
early as 2006.7 Circulating plasma
vesicles are highly heterogeneous and
several distinct classes of membrane
vesicles have been described. They in-
clude microvesicles, ectosomes, mem-
brane particles, exosome-like vesicles,
apoptotic bodies, prostasomes, onco-
somes, or exosomes, and are differenti-
ated based on their biogenesis pathway,
size, ﬂotation density on a sucrose
gradient, lipid composition, sedimen-
tation force, and cargo content.6,8,9
Presently, these vesicles are isolated by
differential and/or density gradient
centrifugation that rely primarily on the
size or density of the vesicles. Because
size and density distribution are not
discretely unique to each class of
membrane vesicles, the present isola-
tion techniques cannot differentiate
between the different classes. Although
immunoisolation techniques using an-
tibodies against speciﬁc membrane
proteins could enhance the speciﬁcity of
membrane vesicle isolation, no mem-
brane protein has been reported to be
unique to a class of membrane vesicles
or to a particular cell type. For example,
although tetraspanins such as CD9,
CD81 have often been used as exosome-
associated markers, their ubiquitous
distribution over the surface membrane
of many cell types suggests a generic
association with membrane vesicles.
Also, such immunoisolation techniques
cannot distinguish between membrane
vesicles, protein complexes, or soluble
receptors. The lack of speciﬁc isolation
technique for each class of these mem-
brane vesicles is further exacerbated
by a lack of nomenclature standard
to unambiguously deﬁne each class ofmembrane vesicle.10 It is also not clear
if the present classiﬁcation of vesicles
describe unique entities.
To circumvent this conundrum and
develop alternative techniques for iso-
lating membrane vesicles, we focus on
membrane lipid as the target for isola-
tion. A deﬁning feature of circulating
membrane vesicles is the derivation of
their bilipid membrane from the plas-
ma membrane. The plasma membrane
is a highly compartmentalized cellular
structure with an ordered distribution of
proteins and lipids that are highly
restricted in their rotational and lateralOCTOBER 2014 Ameridiffusion within the plane of the mem-
brane. This ordered distribution gen-
erates structurally and functionally
unique microdomains, and such micro-
domains have been shown to be critical
for membrane activities such as cell sig-
nalling, cell adhesion, and membrane
trafﬁcking.11 The best characterized
microdomain to date is the lipid raft that
is enriched in cholesterol and saturated
lipids such as sphingolipids. Another
microdomain is the caveolae that are
specialized uncoated cell surface invag-
inations. Caveolae are generally viewed
as a specialized subtype of lipid rafts.can Journal of Obstetrics& Gynecology 380.e2
FIGURE 2
CTB and AV bind unique vesicles
Plasma from a healthy donor was incubated with biotinylated cholera toxin B chain (CTB) or with
biotinylated annexin V (AV). Bound vesicles were extracted with Dynabeads MyOne Streptavidin T1
(Life Technologies, Grand Island, NY) and then assayed for CD9 by enzyme-linked immunosorbent
assay. The CTB- and AV-depleted plasma were then extracted with AV and CTB, respectively. These
second extractions were also assayed for CD9 by ELISA. The relative level of CD9 in CTB-vesicles
before and after extraction with AV, and that in AV-vesicles before and after extraction with CTB were
normalized to that in AV-vesicles before CTB extraction.
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organized by the lipid constituents,
namely, cholesterol and sphingolipids.
Nonlipid raft microdomains have been
reported and these appeared to be
organized by proteins eg, the actin cy-
toskeleton, galectin-1, K- and H-ras.
The compartmentalization of the
plasma membrane into microdomains
with specialized structures and functions
suggest that the biogenesis of each
class of membrane vesicles from the
plasma membrane is microdomain-
speciﬁc. Therefore, the membrane lip-
ids of circulating vesicles could reﬂect
the microdomain from which they
were derived and may determine their
composition and functions. Indeed,
membrane of exosomes that originated
from endosomes is reportedly enriched
in cholesterol and GM1 gangliosides,
and this enrichment appears to distin-
guish exosomes from other membrane
vesicles.8 Cholesterol- and GM1
ganglioside-rich membranes are reﬂec-
tive of lipid rafts that represent the major
sites of endocytosis. Exposed phospha-
tidylserine has been reported to be
present on membrane of several extra-
cellular vesicles including exosomes.8
Although monocytes and macrophages
endothelial cells are known to secrete
vesicles with exposed phosphatidylser-
ines during inﬂammation, circulating
vesicles with exposed phosphatidylserine
in a healthy individual is thought to
originate primarily from platelets.12 To-
gether, the studies on membrane lipids
of circulating vesicles suggest that
circulating vesicles could be differenti-
ated by their membrane phospholipid
composition, speciﬁcally GM1 gan-
gliosides and phosphatidylserines. As
these 2 phospholipids are known to
bind cholera toxin B chain (CTB) and
annexin V (AV), respectively, CTB and
AV are potentially ligands for extracting
different populations of circulating
vesicles.
In this study, we tested if circulating
plasma membrane vesicles could be
fractionated according to their afﬁnity
for CTB and AV, and if these fractionated
vesicles could be used for discovery of PE
biomarkers.380.e3 American Journal of Obstetrics& GynecolMATERIALS AND METHODS
Plasma collection
The recruitment and enrollment of third
trimester PE and matched healthy
pregnant women by KK Women’s &
Children’s Hospital were approved by
the Singhealth Centralized Institutional
Review Board (ref no: CIRB 2011/476/
D). PE was deﬁned as maternal systolic
blood pressure of >140 mm Hg and/or
diastolic blood pressure of >90 mm Hg
on 2 occasions separated by 6 hours and
proteinuria of 300 mg in a 24-hour
period after 20 weeks of gestation as
per guidelines of the American College
of Obstetricians and Gynecologists. Pe-
ripheral blood was collected into ethyl-
enediaminetetraacetic acid vacutainer
tubes, centrifuged, and the plasma sam-
ples were stored at 80C until analysis.
The plasma samples were analyzed
within 3 months and were not freeze-
thaw more than twice.
There was a total of 11 PE patients and
11 healthy pregnant patients (controls)
enrolled. The mean gestation age of PEogy OCTOBER 2014presentation for the 11 PE patients was
30.5 weeks (range, 24.0e35.0 wks). The
mean systolic and diastolic blood pres-
sure of the 11 PE patients were 166 mm
Hg (range, 148e182mmHg) and 97mm
Hg (range, 71e114mmHg), respectively.
The mean gestation of the 11 con-
trol and 11 PE patients at the time
of collection were 31.9 weeks (range,
27.9e36.0 weeks) and 32.4 weeks (range,
28.4e38.0 weeks), respectively. The
mean age of the control and PE patients
were 27.7 years (range, 20e38 years) and
32.2 years (range, 21e38 years), respec-
tively. The mean gravidity of the control
and PE patients were 2.0 (range, 1e5)
and 1.9 (range, 1e3), respectively. The
mean parity of the control and PE
patients were 0.7 (range, 0e3) and 0.2
(range, 0e1), respectively. The mean
BMI of the control and PE patients were
24.8 kg/m2 (range, 18.3e33.2 kg/m2)
and 30.8 kg/m2 (range, 22.3e43.2 kg/
m2), respectively.
None of control patients had comor-
bidity. Nine of the 11 PE patients had
FIGURE 3
Assay for candidate PE biomarkers in AV-vesicles by antibody array
Annexin V (AV)-vesicles were isolated from plasma of preeclampsia (PE) (n¼ 6) and matched healthy pregnant women (n¼ 6). They were then assayed
for previously reported PE biomarkers using commercially available antibody arrays. The relative level of each marker was normalized to that in the AV-
vesicles of healthy pregnant women.
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One PE patient subsequently developed
eclampsia. One PE patient was severely
obese (BMI 43.2 kg/m2), whereas another
had developed gestational diabetes.
Of the 11 control and 11 PE patients, 6
control and 6 PE patients were processed
for analyses using both mass spectrom-
etry and a commercially available array
of antibodies. The remainder 5 control
and 5 PE patients were processed for
analysis using enzyme-linked immuno-
sorbent assay (ELISA) for candidate
biomarkers that were not covered in the
standard commercial antibody array.
Isolation of GM1 ganglioside- and
phosphatidylserine-rich membrane
vesicles
CTB (SBL Vaccin AB, Stockholm, Swe-
den) and AV (Biovision, San Francisco,CA) was biotinylated using Sulfo-
N-hydroxysulfosuccinimide Biotin
(Thermo Scientiﬁc, Waltham,MA) as per
manufacturer’s instruction. Ten microli-
ters of plasma from each healthy and
preeclampsia patients were incubated
with 0.5 hg biotinylated CTB or 0.5 hg
biotinylated AV in 100 mL binding buffer
(2.5 mM calcium chloride, 0.01 M Hepes
[Life Technologies, Grand Island, NY],
and 0.14 M sodium chloride) for 30 mi-
nutes at 37C in a rotating tube. At the
same time, 100 mL of Dynabeads MyOne
Streptavidin T1 (Life Technologies) was
washed thrice with 100 mL wash buffer
(0.1% bovine serum albumin in phos-
phate buffer saline) by vortex mixing the
beads, immobilizing the beads with a
magnet, and removing the supernatant
for each wash. After removing the last
wash buffer, the beads were resuspendedOCTOBER 2014 Ameriin 100 mL binding buffer. Five microliters
of the washed beads were then added to
the plasma-CTB or plasma-AV reaction
mix and incubated with rotation for
30 minutes. The beads were immobilized
with a magnet and the supernatant was
removed. The beads were then washed
thrice with 200 mL AV binding buffer
as described above. The bead-captured
membrane vesicles were then analyzed
by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-
PAGE), ELISA, antibody array, and mass
spectrometry.SDS-PAGE
The beads were boiled in 28 mL of
a standard denaturing/reducing SDS-
PAGE loading buffer and resolved on
4-12% SDSepolyacrylamide gels.can Journal of Obstetrics& Gynecology 380.e4
FIGURE 4
Assay for candidate PE biomarkers in CTB-vesicles by antibody array
Cholera toxin B chain (CTB)-vesicles were isolated from plasma of preeclampsia (PE) (n¼ 6) and matched healthy pregnant women (n¼ 6). They were
then assayed for previously reported PE biomarkers using commercially available antibody arrays. The relative level of each marker was normalized to
that in the CTB-vesicles of healthy pregnant women.
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To assay for membrane proteins such
as CD9, the beads were incubated with
1:500 dilution of mouse antihuman CD9
antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) with rotation for 30
minutes. The beads were then im-
mobilized and supernatant was removed,
washed thrice with 200 mL wash buffer,
and then incubated with 1: 5000 HRP
conjugated donkey antimouse IgG anti-
body (Santa Cruz Biotechnology) for
30 minutes with rotation at room tem-
perature. After washing, the beads were
incubated with 100 mL Amplex Red
Substrate (Life Technologies) for 30 mi-
nutes and ﬂuorescent intensity was
measured at 530/590 ƞm (excitation/
emission). To assay for luminal proteins,
the bound vesicles are lysed with 100 mL
of cell lysis buffer (Biovision). The lysed380.e5 American Journal of Obstetrics& Gynecolvesicles were then biotinylated by adding
10 mL 1:4000 diluted 10 mM Sulfo-NHS
Biotin (Thermo Scientiﬁc, #21217). To
assay for CD9, soluble fms-like tyrosine
kinase-1, brain natriuretic peptide
(BNP), atrial natriuretic peptide (ANP),
placenta growth factor (PlGF), magnetic
bead conjugated antibody speciﬁc for the
protein of interest was then added. The
antibody-bound protein was then
immobilized by magnet and washed
thrice as described above. The target
protein was assayed using Amplex Ultra
Red Substrate as described earlier.
Antibody array
For antibody array, CTB- and AV- vesi-
cles were isolated from each of 6 PE
patients and 6 healthy controls by incu-
bating 30 mL of plasma with 1.5 ƞg
biotinylated CTB or AV, respectively.ogy OCTOBER 2014The isolated vesicles were lysed as de-
scribed previously and analyzed for
proteins using RayBio Custom Quanti-
body Array (cat. QAH-CUST) according
to manufacturer’s instructions (RayBio-
tech, Norcross, GA).
Mass spectrometry
Formass spectrometry, 300 mL of pooled
plasma from either 6 PE patients or 6
healthy controls was incubated with 15
ng CTB or AV to isolate CTB- and AV-
vesicles. The 60 mL of the washed beads
prepared as described above were then
added to the plasma-CTB or plasma-AV
reaction mix and incubated with rota-
tion for 30 minutes. The beads were
immobilized with a magnet and the su-
pernatant was removed. The beads were
then washed thrice with 200 mL AV
binding buffer as described above. The
FIGURE 5
Assay for candidate PE biomarkers in AV-vesicles by ELISA
Cholera toxin B chain (CTB)- and annexin V (AV)-vesicles were isolated from plasma of preeclampsia (PE) (n¼ 5) and matched healthy pregnant women
(n¼ 5). They were then assayed for previously reported PE biomarkers by ELISA. The relative level of each marker in CTB- or AV-vesicles was normalized
to that in the corresponding vesicles of healthy pregnant women.
ELISA, enzyme-linked immunosorbent assay.
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on a protein gel. Each gel lane was sliced
separately into 8 pieces. The gel pieces
were destained; proteins in the gel were
reduced by 10 M dithiothreitol at 56C
for 1 hour and alkylated by 55 mM
iodoacetamide for 45 minutes in the
dark at room temperature. Tryptic di-
gestion was performed by using porcine
trypsin (Sequencing Grade Modiﬁed,
Promega, WI) overnight. The tryptic
peptides were extracted by 5% formic
acid in 50% acetonitrile and vacuum
dried by speedvac.13 Each dried fraction
was reconstituted in 100 mL of 0.1%
formic acid and analyzed using a linear
ion trap–Fourier transform (LTQ–FT)
Ultra mass spectrometer (Thermo Elec-
tron, Bremen, Germany) coupled with a
ProminenceTM HPLC unit (Shimadzu,
Kyoto, Japan). For each analysis, samples
was injected from an autosampler (Shi-
madzu) and concentrated in a Zorbax
peptide trap (Agilent, Palo Alto, CA).
The peptide separationwas performed ina capillary column (75 mm inner
diameter  15 cm) packed with C18 AQ
(5 mm particles, 300 Å pore size;
Michrom Bioresources, Auburn, CA).
Mobile phase A (0.1% formic acid in
H2O) and mobile phase B (0.1% formic
acid in acetonitrile) were used to estab-
lish the 90 minute gradient comprising
3 minutes of 0-5% B and then 52 mi-
nutes of 5-25%B followed by 19minutes
of 25-80% B, maintenance at 80% B for
8 minutes, and ﬁnally reequilibration at
5% B for 8 minutes. The HPLC system
was operated at a constant ﬂow rate of
30 mL minute1, and a splitter was used
to create an effective ﬂow rate of
approximately 300 nL minute1 at the
electrospray emitter. The sample was
injected into an LTQ-FT through an
Advance CaptiveSpray source (Michrom
Bioresources) with an electrospray po-
tential of 1.5 kV. The gas ﬂow was set at
2, ion transfer tube temperature was
180C, and collision gas pressure was
0.85 millitorr. The LTQ-FT was set toOCTOBER 2014 Ameriperform data acquisition in the positive
ion mode as described previously.13
Brieﬂy, a full mass spectrometry (MS)
scan (350e1600m/z range) was acquired
in the FT-ICR cell at a resolution of
100,000. The linear ion trap was used to
collect peptides and to measure peptide
fragments generated by CID. The 10
most intense ions above a 500-count
threshold were selected for fragmenta-
tion in CID (MS2). For each experiment,
MS/MS (dta) spectra of the 8 gel fractions
were combined into a single mascot
generic ﬁle by a home-written program.
Protein identiﬁcation was achieved by
searching the combined data against the
international protein index human pro-
tein database (version 3.34; 69,164 se-
quences, 29,064,825 residues) via an
inhouse Mascot server (version 2.3.02;
Matrix Science, London, UK). The search
parameters were: a maximum of 2 missed
cleavages using trypsin; ﬁxed modiﬁca-
tion was carbaminomethylation of cys-
teine, and variable modiﬁcations wascan Journal of Obstetrics& Gynecology 380.e6
FIGURE 6
Relative distribution of proteins in the CTB- and AV-vesicles of PE
patients and healthy pregnant women
The proteome of CTB- and AV-vesicles of PE patients (n¼ 6) and healthy pregnant women (n¼ 6)
was analyzed by mass spectrometry. The proteins in each of the vesicles were compared and their
distribution represented by Venn diagram.
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TABLE 1
63 proteins only in CTB
evesicles of PE patients (n[ 6)
Proteins
ANTXR1 GGT1 LONRF3
APC HSPA5 MMP7
APOA1 HSPA7 NF1
APOC1 IGFBP3 NID1
APOC2 IGKV2-40 NONO
APOE IGLV8-61 NT5C3L
ARFIP1 INHBC ORM1
ARL5B INHBE PCF11
ATPAF1 IPI00045460 PEG3
C7 IPI00385253 PRL
C9orf4 IPI00385555 PRX
CD37 IPI00387025 RELN
CDC2L1 IPI00479426 RPS6
CDC6 IPI00796011 SAA1
CDKL2 IPI00827643 SERPINA6
CIB2 KIF27 TFAP2E
CSHL1 KRT27 THBS3
E2F7 KRT28 UBA1
EFEMP1 KSR2 UNC13B
F13A1 LOC100292046 VPS4A
GCA LOC441687 WDR60
CTB, cholera toxin B chain; PE, preeclampsia.
Tan. Biomarker discovery in preeclampsia using
extracellular vesicles. Am J Obstet Gynecol 2014.
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ances were set to 10 ppm and 0.8
Da for peptide precursor and fragment
ions respectively. Protein identiﬁcation
was accepted as true positive if 2 different
peptides were found to have scores greater
than the homology or identity scores.
Statistical analysis
Statistical analysis was performed using
ManneWhitneyU test. Differences were
considered to be statistically signiﬁcant
when the P values were less than .05.
RESULTS
CTB and AV extracted protein
containing vesicles from plasma
Plasma was incubated with biotinylated
CTB or AV followed by streptavidin-380.e7 American Journal of Obstetrics& Gynecolconjugated magnetic beads. After exten-
sive washing, the beads were boiled in a
protein reducing and denaturing buffer,
and analyzed by SDS-PAGE for protein
(Figure 1). The amount of protein
extracted from 5 mL plasma by CTB or
AV was less than that in 0.01 mL plasma
or less than 0.1% of the starting protein
concentration. Despite the relatively low
resolution of a 2D-gel, there were distinct
differences in the protein proﬁle in the
CTB- and AV-lipid vesicles (Figure 1).
Presence of distinct CTB- and
AV-vesicle populations in the plasma
Plasma was ﬁrst extracted for either
CTB- or AV-vesicles followed by extrac-
tion for AV- and CTB-vesicles, respec-
tively. The extracted vesicles were thenogy OCTOBER 2014assayed for CD9, a ubiquitousmembrane
protein which was used here as a surro-
gate marker for plasma membrane. The
level of CD9 in CTB-vesicles was similar
before and after depletion with AV
(Figure 2). Likewise, the level of CD9
in AV-vesicles was similar before and af-
ter depletion with CTB. Because neither
of the vesicles was depleted by extraction
of the other vesicle, the 2 vesicles did
not share an afﬁnity for either ligands
and were distinct populations.
Candidate biomarkers for PE
segregated differently in circulating
CTB- and AV-vesicles of
preeclampsia and healthy pregnant
women
Vesicles were isolated from plasma
of preeclampsia and matched healthy
TABLE 2
198 proteins present in CTB-vesicles of both PE (n[ 6) and healthy pregnant women (n[ 6)
Proteins
A1BG C8G FGA IPI00384392 KRT8 RAB10
ACTB C9 FGB IPI00384401 KRT9 RAB15
ACTBL2 CAMP GC IPI00384407 LBP RAB1B
ADAM12 CASP12 GDF15 IPI00385264 LCP1 RAB35
AGT CD14 GH2 IPI00385985 LOC100126583 RAB8A
AHSG CD5L GPLD1 IPI00387026 LOC100290320 RAN
AMBP CDADC1 GPX3 IPI00387106 LOC100291682 RARRES2
APCS CDC5L GSN IPI00387116 LOC401847 SAA4
APOA2 CDH1 HAUS3 IPI00387118 LOC55908 SCFV
APOA4 CDH23 HBB IPI00783024 LPA SEPP1
APOA5 CDH5 HBD IPI00791534 LRRC8B SERPINA10
APOB CETP HP IPI00807428 LYZ SERPINA3
APOC3 CFB HSP90AA1 IPI00816799 MAGT1 SERPINA4
APOC4 CFH HSP90B1 IPI00829827 MASP2 SERPINC1
APOD CLTC IGFALS IPI00830088 MGAT1 SERPING1
APOF CLU IGHA1 IPI00909649 MGP SHBG
APOL1 COL18A1 IGHG2 IPI00922295 PCMT1 SIGLEC16
APOM COL6A3 IGHG4 IPI00940451 PF4 SIL1
ASPN CP IGHM IPI00941961 PGLYRP2 SPP2
ATP6AP2 CPB2 IGHV3-48 IPI00944652 PLTP SRI
B4GALT1 CRP IGJ ITGA2B PLXND1 SVEP1
BMP1 CSH1 IGK@ ITIH1 PON1 TF
C1QC DAK IGKV3-20 ITIH2 PON3 THBS1
C1R DEFA1 IGLC1 ITIH3 PPBP THBS4
C1RL DNAH6 IGLV7-43 ITIH4 PRDX6 THSD1
C1S EBI3 IPI00003469 KRT1 PRG4 TLL2
C20orf3 ENO1 IPI00003470 KRT10 PRKDC TRAP1
C3 F2 IPI00007899 KRT14 PROS1 TSKU
C4A F5 IPI00186448 KRT2 PRSS3 TTR
C4B F7 IPI00382420 KRT4 PSG1 UBE2N
C4BPA FBLN1 IPI00382436 KRT5 PSG4 VCL
C5 FBLN5 IPI00382440 KRT6B PZP VTN
C8B FETUB IPI00382481 KRT77 QSOX1 VWF
CRP, C reactive protein; CTB, cholera toxin B chain; PE, preeclampsia.
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ajog.org Obstetrics Researchpregnant women. They were then as-
sayed for the presence of previously re-
ported preeclampsia biomarkers using
either ELISA or a commercially available
antibody array. Plasma from 2 differ-
ent sets of preeclampsia patients andmatched healthy controls were used;
1 for each assay.
Using a commercially available array
of antibodies, CTB- andAV-vesicles from
6 PE patients and 6 matched healthy
controls were assayed for angiotensin-OCTOBER 2014 Americonverting enzyme 2, angiopoietin 1, C
reactive protein, E-selectin, endoglin
(CD105), growth hormone, interleukin-
6, P-selectin, plasminogen activator
inhibitor-1 (PAI-1), PlGF, procalcitonin,
S100b, tumor growth factor b, tissuecan Journal of Obstetrics& Gynecology 380.e8
TABLE 3
155 proteins present only in CTB-vesicles of healthy pregnant women (n[ 6)
Proteins
A2ML1 CMTM5 IGLV306 LOC653879 RB1CC1
ACTN4 CRTAC1 IGLV3-25 LTF RBP4
ADH4 CXCL12 IPI00029863 MAP2K2 RCTPI1
AFM CYB5D2 IPI00259932 MASP1 RHOA
ALB DNAH3 IPI00382421 MDFIC RNF123
ANTXR2 EEF1A1 IPI00383016 MOBKL1B S100A8
ANXA7 ERBB4 IPI00387027 MPP1 SAR1B
ANXA8L1 ETV7 IPI00387101 MTHFD1 SDPR
APOH FAM21A IPI00387105 MYH14 SEMA3B
ARF1 FBXO7 IPI00736860 NAPA SERPIND1
ARF6 FCER1G IPI00748607 NID2 SFRS2IP
ARHGAP1 FGG IPI00827500 NSF SLC25A18
C19orf30 FGL1 IPI00827891 NSMAF SMARCC2
C19orf68 FMO5 IPI00829590 OGT SMC3
C2 GAPDH IPI00829803 OXSR1 SNORA67
C20orf114 GP1BB IPI00855844 PAFAH1B2 SPTA1
C20orf94 GP9 IPI00874178 PCBP2 TAGLN2
C22orf40 GPX1 IPI00945820 PCYOX1 TIMP2
C4BPB GSTK1 ITGB3 PDCD6IP TRIM28
CCT6A GSTM4 KIAA1409 PGK2 TRIM33
CCT8 GTF2H1 KLKB1 PLUNC TTC23L
CD36 HBA2 KRT13 PPIA TUBB1
CDAN1 HBZ KRT15 PRPS1 UBC
CDC10L HLA-C KRT84 PRPSAP2 UBE2M
CDC42 HPR LALBA RAB11B UBXN7
CDC73 HSP90AB1 LECT2 RAB14 WNT16
CDK5 HSPB1 LMAN2 RAB28 YKT6
CDKN1B HTRA1 LOC100289960 RAB5C YWHAQ
CFL1 HYOU1 LOC100292483 RAB8B YWHAZ
CIDEB IGHD LOC440786 RAC2 ZNF645
CLIC1 IGKC LOC652128 RASSF6 ZNHIT1
CTB, cholera toxin B chain; TIMP, tissue inhibitor of metallopeptidase.
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Research Obstetrics ajog.orginhibitor of metallopeptidase 1, and tu-
mor necrosis factor a (Figures 3 and 4).
Four proteins, namely CD105, in-
terleukin-6, PlGF, and tissue inhibitor
of metallopeptidase 1 were signiﬁcantly
elevated in only CTB- but not AV-vesicles
of preeclampsia patients. Another 4 PAI-
1, procalcitonin, S100b, tumor growth380.e9 American Journal of Obstetrics& Gynecolfactor b were elevated in both CTB- and
AV-vesicles of PE patients.
For other candidate biomarkers that
were not covered in the antibody array,
CTB- and AV-vesicles from 5 PE patients
and 5 matched controls were assayed
by ELISA. The proteins assayed were
CD9, vascular endothelial growth factorogy OCTOBER 2014receptor 1 (VEGFR1), BNP, ANP, and
PlGF. ANP was signiﬁcantly increased
in the CTB- but not AV-vesicles of PE
patients although VEGFR1, BNP, and
PlGF were signiﬁcantly increased in both
CTB- and AV-vesicles of PE patients
(Figure 5). The statistically signiﬁcant
increased PlGF level (P ¼ .047) in
TABLE 4
80 proteins present in only AVevesicles of PE patients (n[ 6)
Proteins
A1BG APOA2 H2AFV KRT6B
BMP1 APOA5 HTRA1 KRT6C
CDH23 APOC3 HYOU1 KRT77
CFH ARHGAP1 IGHA1 KRT84
COL18A1 ASPN IGHG3 LOC440786
DLEC1 B4GALT1 IGLV3-25 LOC652128
EBI3 BNIP2 IPI00003469 LYZ
HTR7P C1QB IPI00384392 MYBL1
IGHM C1QTNF6 IPI00385985 PCBP2
IPI00003470 C5 IPI00387115 PLUNC
IPI00382420 CD300LG IPI00748607 PLXND1
IPI00384407 CDH18 IPI00783024 RFPL2
IPI00736860 CP IPI00829841 RPL32
IPI00829956 CRP IPI00903033 SPP2
IPI00830018 DMRTA1 IPI00909484 SYNPR
IPI00830088 DSP IPI00910738 TF
KRT17 F5 KIAA0586 TLL2
KRT8 FAM21A KLKB1 TLN2
AFM FGG KRT14 TRIM33
ANXA5 GP1BB KRT5 TSNAXIP1
AV, annexin V; CRP, C reactive protein; PE, preeclampsia.
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ajog.org Obstetrics ResearchAV-vesicles of PE patients contrasted
with its insigniﬁcant increase (P ¼ .055)
when assayed using antibody arrays. This
discrepancy could be a statistical anom-
aly as the 2 assays were conducted using
small samples of 2 independent sets
of patients and controls (P ¼ .055).
CD9 was signiﬁcantly decreased in the
CTB- but signiﬁcantly increased in AV-
vesicles of PE patients.
Together, these 2 studies demon-
strated that previously reported candi-
date biomarkers for PE were present and
differentially distributed in CTB- and
AV-vesicles of PE patients relative to
matched healthy controls.
Proteomic analysis of the CTB- and
AV-vesicle populations in the plasma
of preeclampsia and healthy
pregnant women
For a comprehensive proteomic analysis
of the CTB- and AV-vesicles from thepooled plasma of 6 preeclampsia and
6 healthy pregnant women, proteins in
these vesicles were identiﬁed by mass
spectrometry. A total of 285 and 269
proteins were detected in the CTB- and
AV-vesicles of PE patients respectively,
whereas 420 and 322 proteins were
detected in those of healthy controls
(Figure 6). Of the 285 and 420 proteins
in the CTB-vesicles of PE and healthy
pregnant women, 198 proteins were
found in the CTB vesicles of both pa-
tient groups. Likewise, 165 proteins
were found in the AV-vesicles of both
patient groups. Therefore, the remain-
ing proteins that were present only in
the vesicles of either PE or healthy
pregnant women, ie, 87 CTB-proteins
of PE patients, 104 AV-proteins of PE
patients, 222 CTB-proteins of healthy
pregnant women and 157 AV-proteins
of healthy pregnant women (Figure 6)
represented candidate PE biomarkersOCTOBER 2014 Americ(Tables 1 and 2). Twenty-four of the 87
CTB- and 104 AV-proteins were found
in both vesicles whereas 67 of the 222
CTB- and 157 AV-proteins in the con-
trol group were present in both vesicles
(Table 3). Eleven of the 87 CTB-proteins
in PE patients were present in AV-
vesicles of healthy pregnant women
whereas 17 of the 104 AV-proteins in PE
patients were present in CTB-vesicles of
the matched control group (Tables
4-10). These observations indicated that
the candidate biomarkers were distrib-
uted in all possible permutations be-
tween the 2 vesicle types of PE patients
vs healthy pregnant women. Therefore,
a single PE biomarker could be differ-
entially expressed in the 2 vesicles of a
pregnant woman. This differential
expression would potentially increase
the robustness of the biomarker and
facilitate comparison between patients
by determining the ratio of the
biomarker in the 2 vesicles.
COMMENTS
This study demonstrated that plasma
contained at least 2 distinct populations
of membrane vesicles that could be
isolated according to their afﬁnities for
CTB and AV, and that their protein car-
gos are distinct from each other and
reﬂective of the disease state of the
patients. As CTB and AV bind phos-
pholipids, GM1 ganglioside and phos-
phatidylserine respectively, and as
phospholipids are bipolar, any CTB- or
AV-bound phospholipids from aqueous
physiological ﬂuid would be a micelle or
vesicle (as this is the thermodynamically
stable conﬁguration for phospholipids in
aqueous solution). Therefore, CTB- or
AV-afﬁnity isolation techniques would
be highly speciﬁc for the isolation of
phospholipid membrane vesicles with
minimal contamination of large non-
vesicle biologic complexes or soluble
proteins.
This is the ﬁrst description of plasma
vesicles that bind exclusively to either
CTB or AV. As such, the origin and
physiologic functions of these vesicles
are unknown, and, their roles in the
pathology of diseases have not been
elucidated. Nevertheless, the strong as-
sociation between their protein cargoan Journal of Obstetrics& Gynecology 380.e10
TABLE 5
165 proteins present in AV-vesicles of both PE (n[ 6) and healthy
pregnant women (n[ 6)
Proteins
A2ML1 CDADC1 IGHG2 KRT4 RAB28
AGT CDC42 IGHG4 KRT9 RAB35
ALB CDC6 IGK@ LALBA RAB8A
AMBP CDH5 IGKC LBP RAC2
ANXA7 CETP IGKV3-20 LOC100126583 RAN
APCS CFB IGKV3D01 LOC100290320 RASSF6
APOB CHMP4B IGLC1 LOC100291682 RB1CC1
APOC1 CLTC INHBC LPA RBP4
APOC2 CLU IPI00007899 LRRC8B RPS6
APOC4 COL6A3 IPI00029863 LTF S100A8
APOD CPB2 IPI00382436 MAGT1 SAA1
APOE CSH1 IPI00382440 MASP1 SAA4
APOF DAK IPI00382481 MASP2 SAR1B
APOL1 DEFA1 IPI00384401 MGP SEMA3B
ARF1 EFEMP1 IPI00385264 MYH14 SEPP1
ATP6AP2 FBLN1 IPI00387106 NSMAF SERPINA3
C19orf30 FBLN5 IPI00387116 PAFAH1B2 SERPINA6
C1QC FGA IPI00387118 PCYOX1 SERPINC1
C1R FGB IPI00783287 PDCD6IP SERPIND1
C1RL GAPDH IPI00807428 PF4 SERPING1
C1S GC IPI00816799 PGK2 SHBG
C20orf114 GH2 IPI00827643 PGLYRP2 SIGLEC16
C20orf3 GPLD1 IPI00829803 PLTP SLC8A3
C3 GPX3 IPI00829827 PON1 SMO
C4A HAUS3 IPI00909649 PON3 SVEP1
C4B HBA2 IPI00922295 PPBP THBS1
C4BPA HBB IPI00944652 PRDX6 TRAP1
C4BPB HP ITGA2B PRG4 TSKU
C8B HPR KRT1 PROS1 TTR
C9 HSP90AA1 KRT10 PRSS3 VCL
CASP12 HSP90AB1 KRT13 PSG1 VTN
CD14 HSP90B1 KRT2 QSOX1 VWF
CD5L IGFALS KRT27 RAB15 YWHAZ
AV, annexin V; PE, preeclampsia.
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TABLE 6
90 proteins in only AVevesicles
of healthy pregnant women
(n[ 6)
Proteins
ACTB F9 LOC401847
ACTBL2 FETUB LOC55908
ADAM12 GBF1 MGC15705
AHSG GSN MINPP1
ALG9 HBD OAF
ANGPTL6 HK3 OLFM3
ANTXR1 IGJ PALM
APC IGKV2-40 PARD3B
APOA1 IGLV208 PARVB
APOA4 INHBE PCMT1
APOM IPI00011310 PDXP
ARFIP1 IPI00384399 PRKDC
ARHGEF6 IPI00384409 PRL
BICC1 IPI00387025 PRX
BPGM IPI00387026 PSG4
C1orf64 IPI00790470 PZP
C8A IPI00827580 RAB10
C8G IPI00893755 RAB1B
CBR1 IPI00921459 RSU1
CDC5L IPI00940451 SCGB3A1
CDY2B IPI00941961 SERPINA10
COPS8 IPI00952561 SERPINA4
CORO1A ITIH1 SIL1
CSHL1 ITIH2 THBS4
DNAH6 ITIH3 THSD1
EEF1A2 ITIH4 TPCN1
EIF2AK2 KIF27 UBE2D2
ENO1 KRT7 UBE2N
F2 LCAT UBE2V1
F7 LCP1 XPNPEP3
ANGPTL6, angiopoietin 6; AV, annexin V.
Tan. Biomarker discovery in preeclampsia using
extracellular vesicles. Am J Obstet Gynecol 2014.
Research Obstetrics ajog.orgload and disease manifestation impli-
cates an active role in the pathophysi-
ology, and therefore a sentinel for disease
progression and resolution. The exclu-
siveness of the CTB and AV binding380.e11 American Journal of Obstetrics& Gynecafﬁnities for these vesicles indicate that
the lipid compositions of these 2 vesicles
are different and their membrane bio-
genesis originates from different micro-
domains in the plasma membranes. Asology OCTOBER 2014different microdomains are functionally
different, a difference in the origins and
functions of these vesicles could be
inferred. In addition, we noted that
serum is a rich source of platelet micro-
particles but a relatively poor source of
TABLE 7
24 proteins present in both CTB-
and AV-vesicles of only PE
patients (n[ 6)
Proteins
A2M IPI00382483 LRSAM1
C20orf134 IPI00783023 LTBP1
COLEC10 IPI00828156 MMP9
COLEC11 IPI00830044 MMRN1
CRH IPI00890754 POSTN
ERC1 KRT16 SERPINA1
FN1 KRT6A SFTPB
HPX LDHA TM9SF1
AV, annexin V; CTB, cholera toxin B chain; PE,
preeclampsia.
Tan. Biomarker discovery in preeclampsia using
extracellular vesicles. Am J Obstet Gynecol 2014.
TABLE 9
11 proteins present in CTB-
vesicles of PE patients (n[ 6)
and AV-vesicles of healthy
pregnant women (n[ 6)
Proteins
ANTXR1 INHBE
APC IPI00387025
APOA1 KIF27
ARFIP1 PRL
CSHL1 PRX
IGKV2-40
AV, annexin V; CTB, cholera toxin B chain; PE,
preeclampsia.
Tan. Biomarker discovery in preeclampsia using
extracellular vesicles. Am J Obstet Gynecol 2014.
ajog.org Obstetrics ResearchCTB- or AV-binding vesicles, suggesting
that the most of CTB- or AV-binding
vesicles in the plasma were not platelet
microparticles.TABLE 8
67 proteins present in both CTB- and
pregnant women (n[ 6)
Proteins
CD9 ARHGDIA
CDH3 CA1
IPI00219910 CA2
IPI00941428 CAND1
IPI00941443 CAP1
IPI00952572 CAPN1
IPI00382476 CAPNS1
IPI00387113 CGN
IPI00387120 CNDP1
IPI00743194 CPN2
IPI00827875 CUL3
IPI00827646 ENO2
IPI00827695 ENO3
ACTA1 FERMT3
AK1 FLNA
APRT GCLM
ARF4 GSTP1
AV, annexin V; CTB, cholera toxin B chain.
Tan. Biomarker discovery in preeclampsia using extracellulaBased on our current understanding
of membrane vesicles, we speculate that
because the CTB-vesicles were rich in
GM1 ganglioside, they could be derived
from lipid rafts and therefore, were likely
to be exosomes.8 On the other hand, it is
difﬁcult to speculate on the identity of
AV-vesicles as exosomes, microvesicles,
ectosomes and possibly others have
been reported to have exposed phos-
phatidylserines.8 In healthy cells, phos-
phatidylserines are mainly localized on
the inner leaﬂet of the membrane and
this asymmetry is actively maintained
by ATP-dependent aminophospholipid
translocase.14 In dying cells or mem-
brane vesicles where ATP production is
not sustainable, phosphotidylserines
become exposed by spontaneous diffu-
sion between the 2 membrane leaﬂets.
We hypothesize that the absence of
phosphatidylserines in CTB-vesicles
could be due to the characteristic rigid-
ity of the lipid rafts15 from which the
CTB-afﬁnity was supposedly derived.AV-vesicles of only healthy
ILK-2 PSME1
KNG1 PSME2
KPNB1 PSMF1
LOC100133511 RAB6B
LXN RAC1
MYH9 RAP1B
PAFAH1B3 SERPINA11
PCSK9 SERPINA5
PFN1 SERPINA7
PLG SETD4
PPP2R1A STOM
PRDX1 TFRC
PRDX2 TLN1
PROC TUBA1C
PSG3 TUBB2C
PSG8 ZNF878
PSG9
r vesicles. Am J Obstet Gynecol 2014.
OCTOBER 2014 AmericThis rigidity could restrict the diffusion
of lipids and proteins in the plasma
membrane and prevent spontaneous
distribution of phosphatidylserines be-
tween the 2 lipid membranes.
Analysis of CTB- and AV-vesicles in
the plasma of preeclampsia patients and
matched healthy controls revealed that
they carry previously reported bio-
marker candidates for preeclampsia.
However, the relative levels of each
candidate biomarker in each of these 2TABLE 10
17 proteins present in AV-
vesicles of PE patients (n[ 6)
and CTB-vesicles of healthy
pregnant women (n[ 6)
Proteins
AFM IPI00736860
ARHGAP1 IPI00748607
FAM21A KLKB1
FGG KRT84
GP1BB LOC440786
HTRA1 LOC652128
HYOU1 PCBP2
IGLV3-25 PLUNC
TRIM33
AV, annexin V; CTB, cholera toxin B chain; PE,
preeclampsia.
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extracellular vesicles. Am J Obstet Gynecol 2014.
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Research Obstetrics ajog.orgvesicles from plasma of patients and
matched healthy controls were distrib-
uted into nearly all possible permuta-
tions. For example, CD105 was elevated
in CTB- but AV-vesicles of PE patients,
PAI-1 was elevated in both CTB- and
AV-vesicles of PE patients, and CD9 was
reduced in CTB-vesicles but not elevated
in AV-vesicles of PE patients. This
diverse permutation was further vali-
dated by a global proteomic proﬁling of
the vesicles by mass spectrometry. The
CTB- and AV-vesicles of PE patients,
and that of matched healthy pregnant
women not only had proteins that were
unique to each of the 2 pregnant women
cohorts, the CTB- and AV-vesicles in
each women cohorts also had proteins
unique to either the CTB- or AV-vesicles.
Therefore, the CTB- or AV-vesicles in the
plasma represent independent sources
of biomarkers and the use of these vesi-
cles could expand the biomarker dis-
covery potential of plasma by a factor
of 2. This together with the inherent
removal of high abundance plasma pro-
teins during vesicle isolation enhanced
global proteomic analysis as evidenced by
the uncovering of many candidate bio-
markers with less than 1mL of plasma. In
addition, the different distribution of a
protein in the 2 vesicles could be
exploited as a means to normalize the
relative level of a biomarker and facilitate
interpatient comparison. However, the
different distribution of a biomarker in380.e13 American Journal of Obstetrics& Gynecthe 2 vesicles will necessitate the isola-
tion of vesicles not only for biomarker
discovery but also the subsequent bio-
marker assay.
In conclusion, we described a novel
technology to isolate 2 unique classes
of membrane vesicles from the plasma
and demonstrated the tractability of
this technology in interrogating plasma
proteome for low abundance plasma
proteins as candidate PE biomarkers.
This proof of concept for this plasma
vesicle extraction methodology and the
use of the vesicle for biomarker discovery
provide a rationale for the use of CTB-
and AV-vesicles for biomarker discovery
in obstetrics and gynecology and other
medical specialties. -
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